"Trimetrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Descriptor ID |
D016597
|
| MeSH Number(s) |
D03.633.100.786.925
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Trimetrexate".
Below are MeSH descriptors whose meaning is more specific than "Trimetrexate".
This graph shows the total number of publications written about "Trimetrexate" by people in this website by year, and whether "Trimetrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trimetrexate" by people in Profiles.
-
Emax model and interaction index for assessing drug interaction in combination studies. Front Biosci (Elite Ed). 2010 01 01; 2(2):582-601.
-
Applying Emax model and bivariate thin plate splines to assess drug interactions. Front Biosci (Elite Ed). 2010 01 01; 2(1):279-92.
-
Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol. 2002 Jun 15; 20(12):2876-80.
-
Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proc Natl Acad Sci U S A. 2002 Mar 19; 99(6):3400-5.
-
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
-
A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300.
-
Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan. Biochem Pharmacol. 1995 Apr 18; 49(8):1069-78.
-
Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs. 1992 Nov; 10(4):331-5.
-
A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest. 1990; 8(6):619-21.
-
Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline. Isr J Med Sci. 1988 Sep-Oct; 24(9-10):477-82.